BioSpace News Archive

Business

Roche Inks Potential $1.8B Deal With Ascidian to Develop RNA Exon Therapies

Ascidian Therapeutics will receive $42 million upfront from Roche, and up to $1.8 billion in milestone payments and royalties, to discover RNA exon editing candidates for neurological diseases.

June 18, 2024
·
2 min read
·
Tyler Patchen
Policy

5 FDA Decisions to Watch in the Second Half of 2024

The next six months for the FDA are primed to be as groundbreaking as the first six, with Eli Lilly’s donanemab and Lykos Therapeutics’ MDMA-assisted PTSD therapy on the docket, among others.

June 18, 2024
·
6 min read
·
Heather McKenzie
Better Collaboration: 7 Tips for Effective Workplace Communication

By effectively communicating with colleagues, you can improve collaboration as well as your own work experience. It all starts with active listening.

June 18, 2024
·
4 min read
·
Angela Gabriel
BIOSECURE’s Surprise Absence, the $100+ Billion Future Weight-Loss Market, DIA and More

This week’s news ranged from BioSpace’s on-the-ground updates from DIA to safety concerns in clinical trials to BIOSECURE Act updates to new projections that the GLP-1 market could top $100 billion within 10 years.

June 18, 2024
·
2 min read